JP2020510433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510433A5 JP2020510433A5 JP2019547457A JP2019547457A JP2020510433A5 JP 2020510433 A5 JP2020510433 A5 JP 2020510433A5 JP 2019547457 A JP2019547457 A JP 2019547457A JP 2019547457 A JP2019547457 A JP 2019547457A JP 2020510433 A5 JP2020510433 A5 JP 2020510433A5
- Authority
- JP
- Japan
- Prior art keywords
- raav
- capsid
- variant
- sequence
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000234 Capsid Anatomy 0.000 claims 14
- 239000007900 aqueous suspension Substances 0.000 claims 6
- 229920001405 Coding region Polymers 0.000 claims 3
- 241000701022 Cytomegalovirus Species 0.000 claims 3
- 201000003533 Leber congenital amaurosis Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 241000432074 Adeno-associated virus Species 0.000 claims 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 230000003612 virological Effects 0.000 claims 2
- 102100011550 ACTB Human genes 0.000 claims 1
- 101700033661 ACTB Proteins 0.000 claims 1
- 101710032514 ACTI Proteins 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 102100012440 LCA5 Human genes 0.000 claims 1
- 108060004310 LCA5 Proteins 0.000 claims 1
- 201000009710 Leber congenital amaurosis 5 Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
Claims (15)
- ヒトレベルシリンをコードする、配列番号3またはそれと少なくとも80%同一の配列、を含む改変型核酸。
- ヒトレベルシリンをコードする、配列番号3またはそれと少なくとも80%同一の配列、を含む発現カセット。
- 組換えアデノ随伴ウイルス(rAAV)であって、前記rAAVは、AAVカプシドと、その内部にパッケージされたベクターゲノムとを含み、前記ベクターゲノムは:
(a)AAV5’逆向き末端反復(ITR)配列;
(b)プロモーター;
(c)ヒトレベルシリンをコードするコード配列;
(d)AAV3’ITR、
を含む、前記rAAV。 - 前記(c)のコード配列が、配列番号2の天然のヒトレベルシリンコード配列と少なくとも70%同一であるコドン最適化ヒトLCA5である、請求項3に記載のrAAV。
- 前記(c)のコード配列が、配列番号3またはそれと少なくとも80%同一の配列である、請求項3または4に記載のrAAV。
- 前記rAAVカプシドが、AAV7m8もしくはその変異体、AAV8カプシド、AAV6カプシドもしくはその変異体、AAV9カプシドもしくはその変異体、AAV7カプシド、もしくはその変異体、AAV5カプシド、もしくはその変異体、AAV2カプシドまたはその変異体、AAV1カプシドまたはその変異体、AAV3カプシドもしくはその変異体、または、AAV4カプシドもしくはその変異体である、請求項3〜5のいずれか1に記載のrAAV。
- 前記プロモーターが、サイトメガロウイルス(CMV)プロモーター、または、CMVプロモーター配列と、ニワトリベータアクチン(CBA)プロモーター配列とを含むハイブリッドプロモーターである、請求項3〜6のいずれか1に記載のrAAV。
- 前記AAV5’ITR、及び/または、AAV3’ITRが、AAV2由来である、請求項3〜7のいずれか1に記載のrAAV。
- 請求項3〜8のいずれかに記載のrAAVと、眼への送達に適した医薬として許容可能な担体または賦形剤とを含む組成物。
- LCA患者への投与に適した水性懸濁液であって、前記懸濁液は、水性懸濁液、及び、約1×1010ウイルス粒子〜約1×1012GCまたはウイルス粒子/眼である、LCAの治療薬として有用な組換えアデノ随伴ウイルス(rAAV)を含み、前記rAAVは、AAVカプシドを有し、及び、
(a)AAV 5’逆向き末端反復(ITR)配列;
(b)プロモーター;
(c)ヒトレベルシリンをコードするコード配列;
(d)AAV 3’ITR、を含む、
ベクターゲノムをその内部にパッケージしている、前記水性懸濁液。 - 前記懸濁液が、網膜下または硝子体内注射に適している、請求項10に記載の水性懸濁液。
- 前記rAAVカプシドが、AAV7m8カプシドである、請求項10または11に記載の懸濁液。
- LCAを有する対象の処置のための、請求項3〜8のいずれかに記載のrAAV、請求項9に記載の組成物、または、請求項10〜12のいずれかに記載の水性懸濁液、を含んでなる医薬組成物。
- 前記rAAVを、水性懸濁液において、約1×109〜約1×1013のベクターゲノム/眼(vg/眼)で送達する、請求項13に記載の医薬組成物。
- 前記rAAVを、網膜下または硝子体内に投与する、請求項13または14に記載の医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023002799A JP2023040219A (ja) | 2017-03-01 | 2023-01-12 | 眼疾患の遺伝子治療 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762465649P | 2017-03-01 | 2017-03-01 | |
US62/465,649 | 2017-03-01 | ||
US201762469642P | 2017-03-10 | 2017-03-10 | |
US62/469,642 | 2017-03-10 | ||
PCT/US2018/020470 WO2018160849A1 (en) | 2017-03-01 | 2018-03-01 | Gene therapy for ocular disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023002799A Division JP2023040219A (ja) | 2017-03-01 | 2023-01-12 | 眼疾患の遺伝子治療 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020510433A JP2020510433A (ja) | 2020-04-09 |
JP2020510433A5 true JP2020510433A5 (ja) | 2021-03-18 |
JP7211960B2 JP7211960B2 (ja) | 2023-01-24 |
Family
ID=63370488
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019547457A Active JP7211960B2 (ja) | 2017-03-01 | 2018-03-01 | 眼疾患の遺伝子治療 |
JP2023002799A Pending JP2023040219A (ja) | 2017-03-01 | 2023-01-12 | 眼疾患の遺伝子治療 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023002799A Pending JP2023040219A (ja) | 2017-03-01 | 2023-01-12 | 眼疾患の遺伝子治療 |
Country Status (11)
Country | Link |
---|---|
US (2) | US11564996B2 (ja) |
EP (1) | EP3589738A4 (ja) |
JP (2) | JP7211960B2 (ja) |
KR (2) | KR20230093072A (ja) |
CN (1) | CN110582572A (ja) |
AU (2) | AU2018228881B2 (ja) |
BR (1) | BR112019017327A2 (ja) |
CA (1) | CA3054136A1 (ja) |
IL (1) | IL268946A (ja) |
RU (1) | RU2019130004A (ja) |
WO (1) | WO2018160849A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020013772A (es) * | 2018-06-29 | 2021-05-27 | Wuhan Neurophth Biotechnology Ltd Company | Composiciones y métodos para el tratamiento de la neuropatía óptica hereditaria de leber. |
MX2023008826A (es) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Terapia génica para lipofuscinosis neuronal ceroidea. |
US20220387627A1 (en) * | 2021-06-03 | 2022-12-08 | Hope for Hasti | Vectors and gene therapy for treating cornelia de lange syndrome |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
NZ500546A (en) | 1997-04-14 | 2001-09-28 | Cell Genesys Inc | Methods for increasing the production of high titre stocks of recombinant adeno-associated virus (AAV) |
US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
US6491907B1 (en) | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
EP2369002A1 (en) | 1999-08-09 | 2011-09-28 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
WO2001091803A2 (en) | 2000-06-01 | 2001-12-06 | University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
WO2002082904A2 (en) | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
EP2338900B1 (en) | 2001-11-13 | 2014-01-01 | The Trustees of The University of Pennsylvania | Adeno-associated virus (AAV) Cy.5 sequences, vectors containing the same and uses thereof |
AU2002360291A1 (en) | 2001-12-17 | 2003-06-30 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) serotype 8 sequences |
WO2003104413A2 (en) | 2002-06-05 | 2003-12-18 | University Of Florida | Production of pseudotyped recombinant aav virions |
EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
US8005620B2 (en) | 2003-08-01 | 2011-08-23 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
WO2005013090A2 (en) | 2003-08-01 | 2005-02-10 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
DK2292779T3 (en) | 2003-09-30 | 2017-02-27 | Univ Pennsylvania | ADENOASS-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME AND APPLICATIONS THEREOF |
CN106906241B (zh) | 2005-04-07 | 2020-09-11 | 宾夕法尼亚大学托管会 | 增强腺相关病毒载体功能的方法 |
US7456683B2 (en) | 2005-06-09 | 2008-11-25 | Panasonic Corporation | Amplitude error compensating device and quadrature skew error compensating device |
EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
EP2091966A2 (en) * | 2006-12-01 | 2009-08-26 | Oxford BioMedica (UK) Limited | Promoter construct |
US8969353B2 (en) | 2008-11-07 | 2015-03-03 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
AU2011238708B2 (en) | 2010-03-29 | 2016-02-11 | The Trustees Of The University Of Pennsylvania | Pharmacologically Induced Transgene Ablation system |
US9249425B2 (en) * | 2011-05-16 | 2016-02-02 | The Trustees Of The University Of Pennslyvania | Proviral plasmids and production of recombinant adeno-associated virus |
PL2717893T3 (pl) | 2011-06-08 | 2019-12-31 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby do dostarczania mRNA |
JP6208750B2 (ja) | 2012-06-08 | 2017-10-04 | エスリス ゲーエムベーハーethris GmbH | メッセンジャーrnaの肺送達 |
AU2013287281B2 (en) | 2012-07-11 | 2018-04-26 | The Trustees Of The University Of Pennsylvania | AAV-mediated gene therapy for RPGR x-linked retinal degeneration |
DK2954051T3 (da) | 2013-02-08 | 2019-07-08 | Univ Pennsylvania | Modificeret kapsid til genoverførsel til behandling af nethinden |
CN105209619B (zh) * | 2013-03-11 | 2018-10-12 | 泰莱托恩基金会 | miR-204和miR-211及其用途 |
CN105612253A (zh) * | 2013-03-15 | 2016-05-25 | 费城儿童医院 | 含有填充者/填充物多核苷酸序列的载体及其制备方法 |
US9158889B2 (en) | 2013-04-26 | 2015-10-13 | Oral4D Systems Ltd. | Electronic dental charting |
US9719106B2 (en) | 2013-04-29 | 2017-08-01 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof |
US10392622B2 (en) * | 2014-08-01 | 2019-08-27 | The Trustees Of The University Of Pennsylvania | Compositions and methods for self-regulated inducible gene expression |
-
2018
- 2018-03-01 EP EP18760861.7A patent/EP3589738A4/en active Pending
- 2018-03-01 JP JP2019547457A patent/JP7211960B2/ja active Active
- 2018-03-01 RU RU2019130004A patent/RU2019130004A/ru unknown
- 2018-03-01 BR BR112019017327A patent/BR112019017327A2/pt unknown
- 2018-03-01 KR KR1020237020037A patent/KR20230093072A/ko not_active Application Discontinuation
- 2018-03-01 CA CA3054136A patent/CA3054136A1/en active Pending
- 2018-03-01 WO PCT/US2018/020470 patent/WO2018160849A1/en unknown
- 2018-03-01 AU AU2018228881A patent/AU2018228881B2/en active Active
- 2018-03-01 CN CN201880029279.2A patent/CN110582572A/zh active Pending
- 2018-03-01 KR KR1020197027823A patent/KR102545070B1/ko active IP Right Grant
- 2018-03-01 US US16/489,770 patent/US11564996B2/en active Active
-
2019
- 2019-08-27 IL IL26894619A patent/IL268946A/en unknown
-
2022
- 2022-12-05 US US18/061,633 patent/US20230233709A1/en active Pending
-
2023
- 2023-01-12 JP JP2023002799A patent/JP2023040219A/ja active Pending
-
2024
- 2024-04-24 AU AU2024202693A patent/AU2024202693A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220331409A1 (en) | Factor ix gene therapy | |
JP2021106619A5 (ja) | ||
FI3684423T3 (fi) | Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä | |
JP2021087431A5 (ja) | ||
RU2018116076A (ru) | Модифицированные гены атаксии фридрейха и векторы для генной терапии | |
JP2018148927A5 (ja) | ||
JP2020528734A5 (ja) | ||
JP2019503649A5 (ja) | ||
JP2018537984A5 (ja) | ||
JP2020514286A5 (ja) | ||
JP2020513811A5 (ja) | ||
JP2020510428A5 (ja) | ||
JP2020522269A5 (ja) | ||
JP2018506261A5 (ja) | ||
JP2019513794A5 (ja) | ||
JP7493566B2 (ja) | 筋ジストロフィーを治療するためのマイクロジストロフィン断片のアデノ随伴ウイルスベクター送達 | |
JP2020510433A5 (ja) | ||
JP2020519292A5 (ja) | ||
JP2018510620A5 (ja) | ||
RU2019130004A (ru) | Генная терапия при глазных заболеваниях | |
JP2018526994A5 (ja) | ||
WO2023108159A1 (en) | Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector | |
WO2023111106A1 (en) | Fukutin related protein gene transfer increase using modified itr sequences | |
RU2022112789A (ru) | Аденоассоциированный вирусный вектор, состоящий из белков капсида рнр.в, нуклеиновой кислоты, кодирующей белок smn, и его применение | |
WO2023178339A2 (en) | Methods and compositions for treating tnnt2 related cardiomyopathy with a viral vector |